Joel Greenblatt's CPRX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 141,343 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $2.78 M, representing 0.01% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 120,406 shares. Largest reduction occurred in Q4 2023, reducing 76,504 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2019 | +39,820 | New Buy | 39,820 | $5.30 |
| Q4 2019 | -3,306 | Reduce 8.30% | 36,514 | $3.75 |
| Q1 2020 | +90,420 | Add 247.63% | 126,934 | $3.85 |
| Q2 2020 | -57,062 | Reduce 44.95% | 69,872 | $4.62 |
| Q3 2020 | -37,219 | Reduce 53.27% | 32,653 | $2.97 |
| Q4 2020 | -32,653 | Sold Out | 32,653 | $0.00 |
| Q3 2022 | +50,175 | New Buy | 50,175 | $12.84 |
| Q4 2022 | -31,130 | Reduce 62.04% | 19,045 | $18.60 |
| Q1 2023 | +120,406 | Add 632.22% | 139,451 | $16.58 |
| Q2 2023 | -28,977 | Reduce 20.78% | 110,474 | $13.44 |
| Q3 2023 | +3,532 | Add 3.20% | 114,006 | $11.69 |
| Q4 2023 | -76,504 | Reduce 67.11% | 37,502 | $16.81 |
| Q1 2024 | -2,314 | Reduce 6.17% | 35,188 | $15.94 |
| Q2 2024 | -1,491 | Reduce 4.24% | 33,697 | $15.49 |
| Q3 2024 | +2,444 | Add 7.25% | 36,141 | $19.88 |
| Q4 2024 | +2,812 | Add 7.78% | 38,953 | $20.87 |
| Q1 2025 | +8,356 | Add 21.45% | 47,309 | $24.25 |
| Q2 2025 | +62,416 | Add 131.93% | 109,725 | $21.70 |
| Q3 2025 | +31,618 | Add 28.82% | 141,343 | $19.70 |
Joel Greenblatt's Catalyst Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q3 2019, acquiring 39,820 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Catalyst Pharmaceuticals, Inc. (CPRX) for 25 quarters since Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q1 2023, adding 139,451 shares worth $2.31 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 141,343 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $2.78 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 141,343 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.